US FDA inspection at subsidiary Unit-II ends with one procedural observation

Capex & Operations View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹1660.00

prior close

₹1657.10

announcement price

After-mkt

timing

Nifty Midcap 150market+0.0%-0.4% vs market

Pharmaceuticals peers, median of 173sector-0.3%-0.1% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-1.2

15m

-1.5

30m

-1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4+0.0-0.4-0.3-0.1

Next day

+1.4+0.9+0.4+0.6+0.8

+2.1+2.4-0.3+1.5+0.6

+3.5+2.0+1.4+1.5+2.0

+2.3+1.9+0.3+1.7+0.6

+3.6+2.5+1.0+2.5+1.1

+3.1+0.3+2.8+0.8+2.3

15d

-0.9-4.7+3.8-3.3+2.4

+0.4-2.8+3.2-3.9+4.4

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA inspected Unit-II, an API manufacturing facility of Apitoria Pharma Private Limited (a wholly owned subsidiary of Aurobindo Pharma), located at Kazipally Industrial Area, Sangareddy District, Telangana, from September 7 to September 15, 2026. The inspection concluded with one procedural observation. The company will respond to the US FDA within the stipulated timeline and reaffirmed its commitment to quality and compliance standards.

Likely market impact

Single procedural observation suggests no major compliance issues, supporting uninterrupted US market supplies and subsidiary operations.